Genesis R&D 'Likely' to Form New Subsidiary to Develop Single-Stranded RNAi Tech

The cash-strapped shop is betting that such a unit would embolden investors to back Genesis' ssRNAi technology independent of the company's other RNAi programs.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.